The risk or severity of adverse effects can be increased when Topotecan is combined with Natalizumab. The serum concentration of Topotecan can be increased when it is combined with Terazosin. The risk or severity of adverse effects can be increased when Cabergoline is combined with Topotecan. The serum concentration of Topotecan can be increased when it is combined with Verapamil. The serum concentration of Topotecan can be increased when it is combined with Albendazole. The serum concentration of Topotecan can be increased when it is combined with Probenecid. The serum concentration of Topotecan can be increased when it is combined with Dextromethorphan. The serum concentration of Topotecan can be increased when it is combined with Troleandomycin. The serum concentration of Topotecan can be increased when it is combined with Vinblastine. The serum concentration of Topotecan can be increased when it is combined with Cabazitaxel. The serum concentration of Topotecan can be increased when it is combined with Flurazepam. The serum concentration of Topotecan can be increased when it is combined with Alectinib. The risk or severity of adverse effects can be increased when Docetaxel is combined with Topotecan. The serum concentration of Topotecan can be increased when it is combined with Astemizole. The serum concentration of Topotecan can be increased when it is combined with Methadone. The serum concentration of Topotecan can be increased when it is combined with Triflupromazine. The risk or severity of adverse effects can be increased when Lisuride is combined with Topotecan. The serum concentration of Topotecan can be increased when it is combined with Rabeprazole. The serum concentration of Topotecan can be increased when it is combined with Maprotiline. The serum concentration of Topotecan can be increased when it is combined with Sorafenib. The serum concentration of Topotecan can be increased when it is combined with Nifedipine. The serum concentration of Topotecan can be increased when it is combined with Midazolam. The serum concentration of Topotecan can be increased when it is combined with Cilazapril. The serum concentration of Topotecan can be increased when it is combined with Simvastatin. The serum concentration of Topotecan can be increased when it is combined with Lapatinib. The serum concentration of Topotecan can be increased when it is combined with Tacrine. The serum concentration of Topotecan can be increased when it is combined with Trifluoperazine. The serum concentration of Topotecan can be increased when it is combined with Pravastatin. The serum concentration of Topotecan can be increased when it is combined with Topiroxostat. The serum concentration of Topotecan can be increased when it is combined with Prazosin. The serum concentration of Pazopanib can be increased when it is combined with Topotecan. The serum concentration of Topotecan can be increased when it is combined with Sulfinpyrazone. The serum concentration of Topotecan can be increased when it is combined with Daclatasvir. The serum concentration of Topotecan can be increased when it is combined with Dexamethasone. The serum concentration of Topotecan can be increased when it is combined with Saquinavir. The serum concentration of Topotecan can be increased when it is combined with Pantoprazole. The serum concentration of Topotecan can be increased when it is combined with Ponatinib. The serum concentration of Topotecan can be increased when it is combined with Candesartan. The serum concentration of Topotecan can be increased when it is combined with Captopril. The risk or severity of adverse effects can be increased when Satraplatin is combined with Topotecan. The serum concentration of Ibrutinib can be increased when it is combined with Topotecan. Oleandrin may decrease the cardiotoxic activities of Topotecan. The serum concentration of Topotecan can be increased when it is combined with Nitrendipine. The serum concentration of Topotecan can be increased when it is combined with Digoxin. The risk or severity of adverse effects can be increased when Topotecan is combined with Clozapine. The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Topotecan. The serum concentration of Topotecan can be increased when it is combined with Canagliflozin. The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Topotecan. The serum concentration of Topotecan can be increased when it is combined with Lovastatin. The serum concentration of Topotecan can be increased when it is combined with Fexofenadine. The serum concentration of Topotecan can be increased when it is combined with Mitoxantrone. The serum concentration of Topotecan can be increased when it is combined with Brigatinib. The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Topotecan. The serum concentration of Topotecan can be increased when it is combined with Pimozide. The serum concentration of Topotecan can be increased when it is combined with Indinavir. The serum concentration of Topotecan can be decreased when it is combined with Phenytoin. The risk or severity of adverse effects can be increased when Nicergoline is combined with Topotecan. The serum concentration of Topotecan can be increased when it is combined with Mebendazole. The serum concentration of Topotecan can be increased when it is combined with Desipramine. The serum concentration of Topotecan can be increased when it is combined with Nitrazepam. The serum concentration of Topotecan can be increased when it is combined with Baricitinib. The serum concentration of Topotecan can be increased when it is combined with Elacridar. The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Topotecan. Digitoxin may decrease the cardiotoxic activities of Topotecan. The serum concentration of Topotecan can be increased when it is combined with Aminohippuric acid. The serum concentration of Topotecan can be increased when it is combined with Chloroquine. The serum concentration of Aripiprazole can be decreased when it is combined with Topotecan. The serum concentration of Topotecan can be increased when it is combined with Erlotinib. The serum concentration of Topotecan can be increased when it is combined with Scopolamine. The serum concentration of Topotecan can be increased when it is combined with Biperiden. The serum concentration of Topotecan can be increased when it is combined with Pibrentasvir. Acetyldigitoxin may decrease the cardiotoxic activities of Topotecan. The risk or severity of myelosuppression can be increased when Metamizole is combined with Topotecan. The serum concentration of Topotecan can be increased when it is combined with Mitomycin. The serum concentration of Topotecan can be increased when it is combined with Glyburide. The risk or severity of adverse effects can be increased when Metergoline is combined with Topotecan. The serum concentration of Topotecan can be increased when it is combined with Paroxetine. The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Topotecan. The serum concentration of Topotecan can be increased when it is combined with Diclofenac. The serum concentration of Topotecan can be increased when it is combined with Abemaciclib. The serum concentration of Topotecan can be increased when it is combined with Palmitic Acid. The serum concentration of Topotecan can be increased when it is combined with Alfentanil. The serum concentration of Mevastatin can be increased when it is combined with Topotecan. The serum concentration of Topotecan can be increased when it is combined with Vinorelbine. The serum concentration of Topotecan can be increased when it is combined with Novobiocin. The serum concentration of Topotecan can be increased when it is combined with Daidzin. The serum concentration of Topotecan can be increased when it is combined with Reboxetine. The serum concentration of Topotecan can be increased when it is combined with Lopinavir. The serum concentration of Topotecan can be increased when it is combined with Tolvaptan. The risk or severity of adverse effects can be increased when Topotecan is combined with Leflunomide. The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Topotecan. The serum concentration of Topotecan can be increased when it is combined with Quercetin. The therapeutic efficacy of SRP 299 can be decreased when used in combination with Topotecan. The serum concentration of Saxagliptin can be decreased when it is combined with Topotecan. The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Topotecan. The risk or severity of adverse effects can be increased when Methysergide is combined with Topotecan. The serum concentration of Topotecan can be increased when it is combined with Megestrol acetate. The serum concentration of Topotecan can be increased when it is combined with Cimetidine. The serum concentration of Topotecan can be increased when it is combined with Acetaminophen. The serum concentration of Topotecan can be increased when it is combined with Felodipine. The serum concentration of Topotecan can be increased when it is combined with P-Nitrophenol. The serum concentration of Topotecan can be increased when it is combined with Doxepin. The risk or severity of adverse effects can be increased when NOV-002 is combined with Topotecan. The serum concentration of Topotecan can be increased when it is combined with Rolapitant. The serum concentration of Topotecan can be increased when it is combined with Atazanavir. The serum concentration of Topotecan can be increased when it is combined with Rilpivirine. The serum concentration of Topotecan can be increased when it is combined with Carvedilol. The serum concentration of Topotecan can be increased when it is combined with Amitriptyline. The serum concentration of Fluvastatin can be increased when it is combined with Topotecan. The serum concentration of Pitavastatin can be increased when it is combined with Topotecan. The risk or severity of adverse effects can be increased when Pergolide is combined with Topotecan. The serum concentration of Topotecan can be increased when it is combined with Ivermectin. The serum concentration of Topotecan can be increased when it is combined with Bosutinib. The serum concentration of Topotecan can be increased when it is combined with Posaconazole. The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Topotecan. The serum concentration of Topotecan can be increased when it is combined with Vincristine. The serum concentration of Topotecan can be increased when it is combined with Fentanyl. The serum concentration of Topotecan can be increased when it is combined with Propafenone. The serum concentration of Topotecan can be increased when it is combined with Mefloquine. The serum concentration of Topotecan can be increased when it is combined with Sirolimus. The serum concentration of Topotecan can be increased when it is combined with Azithromycin. The serum concentration of Topotecan can be increased when it is combined with Enalapril. The serum concentration of Topotecan can be increased when it is combined with Isavuconazonium. The serum concentration of Topotecan can be increased when it is combined with Nicardipine. The serum concentration of Topotecan can be increased when it is combined with Etravirine. The serum concentration of Topotecan can be increased when it is combined with Terfenadine. The serum concentration of Rosuvastatin can be increased when it is combined with Topotecan. The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Topotecan. The risk or severity of adverse effects can be increased when Filgrastim is combined with Topotecan. The therapeutic efficacy of Tecemotide can be decreased when used in combination with Topotecan.